Register Login
Register to leave comments
  • News bot Oct. 2, 2025, 6:58 p.m.

    📋 NEKTAR THERAPEUTICS (NKTR) - Financial Results

    Filing Date: 2022-08-04

    Accepted: 2022-08-04 16:23:18

    Event Type: Financial Results

    Event Details:

    Nektar Therapeutics (NKTR) Reports Q3 2022 Financial Results Nektar Therapeutics (NKTR) announced its financial results for the period ending Q3 2022. Key Financial Highlights:
    • Revenue: 5035
    • Net Income: Not disclosed
    • EPS: Not disclosed
    • Cash and equivalents: 77545
      • controlled study of NKTR
      • 358 in 280 patients with systemic lupus erythematosus and recommended that the Phase 2 study continue to completion without modification. The study, which is being conducted by Eli Lilly in partnership with Nektar, will continue as planned and no further unblinding of study data will occur. The IAC review included unblinded interim data from approximately 60% of patients who completed the 24
      • week treatment period. ●In July 2022, Nektar announced the promotion of Jillian B. Thomsen to Senior Vice President (SVP) & Chief Financial Officer. Ms. Thomsen has served as SVP, Finance & Chief Accounting Officer of Nektar since 2008, and is a key member of our Executive Committee. Conference Call to Discuss Second Quarter 2022 Financial Results Nektar management will host a conference call to review the results beginning at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time, Thursday, August 4,

    📊 Key Financial Metrics (Year-over-Year Comparison):

    Metric 2022 2021 Change ($) Change (%)
    Current Assets Property Equipment Net 39.79K 60.51K $-20.72K -34.24%
    Current Assets Operating Lease Right Of Use Assets 69.00K 117.03K $-48.03K -41.04%
    Current Assets Other Assets 2.23K 2.74K $-510.00 -18.59%
    Current Liabilities Accounts Payable 12.35K 9.75K $2.60K +26.66%
    Current Liabilities Other Long Term Liabilities 2.08K 3.59K $-1.51K -42.09%
    Operating Costs And Expenses Total Operating Expenses 138.53K 315.80K $-177.27K -56.13%
    Operating Costs And Expenses Loss From Operations 110.20K 269.40K $-159.19K -59.09%
    Nonoperating Income Expense Net Loss 125.52K 249.46K $-123.94K -49.68%
    Cash Flows From Operating Activities Net Loss 249.46K 248.49K $975.00 +0.39%
    Changes In Operating Assets And Liabilities Other Assets 7.63K 11.59K $-3.96K -34.16%
    Changes In Operating Assets And Liabilities Accounts Payable 2.83K 2.10K $732.00 +34.84%
    Other Assets 2.23K 2.74K $-510.00 -18.59%
    Accounts Payable 12.35K 9.75K $2.60K +26.66%
    Operating Lease Liabilities 20.05K 17.44K $2.61K +14.94%
    Revenue 16.26K 20.46K $-4.19K -20.49%
    Total Operating Expenses 174.42K 138.53K $35.89K +25.90%
    Loss from Operations 152.84K 110.20K $42.63K +38.68%
    Interest Expense 7.23K 13.09K $-5.86K -44.78%
    Interest Income 1.10K 845.00 $251.00 +29.70%
    Net Loss 159.07K 125.52K $33.55K +26.73%

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Nektar Therapeutics
    • CIK: 0000906709
    • Ticker Symbol: NKTR
    • Period End Date: 2022-08-04
    • Document Type: 8-K

Search

News categories